What this means
This trial will test whether exercise and nutrition support slow muscle and strength loss in older adults with diabetes and obesity. It has not reported results yet, so we do not know if it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 65 and over
- Where
- 2 sites
The science
- Registered title
- Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide
- Trial ID
- NCT06497595 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Type 2 Diabetes Mellitus in Obese
- What is tested
- Wegovy (2.4 Mg Dose) + exercise & nutrition, Wegovy (2.4 Mg Dose) + usual care
- Sponsor
- Sheba Medical Center
- Ages
- 65 Years to no maximum
- Dates
- First posted Jul 12, 2024 · updated Jul 21, 2026
Registry summary
This study aims to test whether a multi-disciplinary intervention involving exercise and nutrition can slow down the decline in physical function, muscle strength and mass in older adults (aged 65 and above) with Type 2 diabetes (T2D) and obesity treated with Semaglutide.
The main questions it aims to answer are:
In older people with T2D and obesity, treated with Semaglutide, does a multi-disciplinary intervention of exercise and nutrition compared to standard health recommendations:
- Reduce the rate of decline in muscle mass?
- Reduce the rate of decline in muscle strength?
- Reduce the rate of decline in physical function?
Participants will:
Administer Semaglutide once weekly for 6 months. Visit the clinic once every 8 weeks for checkups and tests. Keep a diary of their food consumption. Participants in the intervention group will participate in an online exercise program and will receive personal nutritional counseling.
Sites (2)
- Hadassah Medical Center, Jerusalem, Israel, Israel
- Sheba medical center, Ramat Gan, Israel, Israel